is...(Checking in now and then!)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just let it unfold. IDK
I call BS on your predictions..
8-12-21
QUOTE.
Oh look at that, I am correct again. I told you all when it started rising a few days back this won't hold any gains. This will drop back to teens next week, Koos will go dark for another month or so. He's made his money for this month
Just stop..
100% agreement on that...
3 Reasons $RGBP Could Be Sold For CASH$$
1) The Company is Down, But Not Out.
2) The Science is MRNA Blockbuster But Bank Account isn’t.
3) Dr Koos is near the End of a long Career.
Three accurate statements... Lets Go $RGBP
I often wonder if any $RGBP patent infringements occured in the course of the Covid-19 Vacine Development by big Pharma world wide? Hmmmm
What are the odds Sid_Vicious song "Something Else" will make 4mil views?
Spot on allright.
Must be proud of this one it's a piece of work.
BARCHART OVERALL AVERAGE 100% BUY. https://www.barchart.com/stocks/quotes/RGBP/opinion
Wow guess they are listening.. LOL Big push for power hour on the way! Up 18milly on 10 day volume average need peeps to keep loading now thru power hour. push thru last bit of resistance at .03 and were movin to higher base!
Believe it or not same Co on both boards and its down 26% today..
$RGBP #2 On Most Read and #3 On Most posted OTC Stocks For So Many Good Reasons.. .03 here we come!
It could be in Dollyland way before then.. MOST all are here to make UPWARD gains on our investments... LOL GLTY and your patience holds out. Lets squeeze these MMs.. My shares are locked at $1.50
If you were Koos with the Time and $$$ in RGBP what would you do? nosedive is ahhh unlikely. Agree? I know what I am expecting.. Patience and possibly see it unfold like ONPH or many other biopharma companies IMO.
Yea bud I have far more patience than you on the .0045 .. the wave is going to blow you out of the water.. :} LMAO
His logos-driven rhetoric is based on logic and reason. His ethos-driven post relies on his reputation. Your Pathos rhetoric is based on emotion. Advertisements tend to be pathos-driven.
What would valuation of just one of these 2 cancer treatments in full clinical trials bring to the speculative RGBP PPS?
Not to mention the RGBP licensing deals are 2nd and 4th in CDC list of cancers.
This should not be minimized in the near or long term. What is the valuation on these 2 therapies alone in the pipeline at present? Guesses?
What were the leading causes of cancer death in 2019?
Lung cancer was the leading cause of cancer death, accounting for 23% of all cancer deaths. Other common causes of cancer death were cancers of the colon and rectum (9%), pancreas (8%), female breast (7%), prostate (5%), and liver and intrahepatic bile duct (5%). Other cancers individually accounted for less than 5% of cancer deaths.
MANY THANKS FROM US ALL WITH YOUR PERSPECTIVES DR.
Alot of companies will see a big shift in volume between now and after the August deadline as TDA alone has over 3000 of the 11000 on the OTC on the list to drop from buying.. like 25%.. that's huge.... no doubt RGBP can make great gains on that shift alone.. going current..
Hope he let's news drip out for a week or 2...keep the momentum going.. lotsa peeps be diving on in this over the next week!
I knew yesterday's 911 was right..on..go$RGBP
Exactly just boiler plate statements they have to put in..
RGBP Stars and moons have aligned for a breakout and I am over and out..zzzzzZ
Three signs that a biotechnology company will soon be sold for big money:
1) Your Company is Down, But Not Out.
2) Your Science is Fabulous. Your Bank Account isn’t.
3) Your Controlling Shareholder is at the End of Career.
Stole from the article... but true statements for $RGBP
Thanks there all good after 60 if you still breathin..
Here is 2 of the court orders...
10/21/2020
STIPULATION AND PROTECTIVE ORDER REGARDING CONFIDENTIAL INFORMATION
https://1drv.ms/b/s!Au2nBApcrQEIi81O56C38aEt45NZqA?e=AlB0dN
03/12/2020 HERE IS DAVID KOOS ANSWER TO COMPLAINT.
https://1drv.ms/b/s!Au2nBApcrQEIi81PcjQbwGGFG-iLgg?e=Ua5nYN
Notice the THIRTY-ONE AFFIRMATIVE DEFENSE STATEMENTS KOOS MADE AGAINST CHEMDIV..
THESE BELOW ARE SOME OF THE VERY INTERESTING DEFENSIVE STATEMENTS...
SECOND AFFIRMATIVE DEFENSE
The damages allegedly suffered by Plaintiff, if any, were the result of Plaintiff'sown acts or omissions and/or the acts or omissions of third parties.
SIXTH AFFIRMATIVE DEFENSE
Plaintiff's claims are barred because Plaintiff frustrated, hindered, and prevented Defendant from performing.
FIFTEENTH AFFIRMATIVE DEFENSE
Defendant fully tendered and/or performed all contractual, statutory, and all other duties owed to Plaintiffunder applicable law, if any. Therefore, the Complaint, and the causesof action therein, arebarred.
IMO THERE IS MORE TO THIS SUIT THAN JUST RENUMERATION FOR SERVICES.
TWENTY-EIGHTH AFFIRMATIVE DEFENSE
Defendant has performed all acts and obligations required of him under the contracts or agreements, if any, to which he was party, other than those rendered impossible due to the actions or inactions of Plaintiff.
Still Holdin My Shares.. Maybe today is the big day we are waiting on 911 in the trades yesterday.. GLTA
Like the article says "Currently under heavy accumulation RGBP has been attracting some pretty heavy hitters who see big things in the works here."
that is how I see it..
"RGBP is in beast mode right now and is the most talked about small cap stock..."
Nice writeup...
https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-biotech-sleeper-sitting-on-a-major-league-patent-portfolio/132392/
Disclosure: we hold no position in RGBP either long or short and we have not been compensated for this article....
Bought more 2 days this week not sellin be patient my friends.. new millionaires club forming soon..
DAVID KOOS THIRTY-ONE AFFIRMATIVE DEFENSE ACTIONS...LISTED..
I am no attorney but my thought on the Lawsuit is there was something possibly other than monetary payment going on that Mr Koos was wanting to defend against. According to the
ELEVENTH AFFIRMATIVE DEFENSE OF the 31 filed.
The causes of action alleged in the Complaint are barred, in whole or in part, on the ground that intervening, subsequent, intentional, legal, and/or negligent acts of one or more persons or parties other than Defendant caused the happening of the alleged incident and the alleged injury, loss, and damage
complained of.
FOURTEENTH AFFIRMATIVE DEFENSE
The damages allegedly suffered by Plaintiff were the result of Plaintiff's negligence or other
intentional acts and/or the negligence or acts of third parties for which Defendant was not responsible.
FIFTEENTH AFFIRMATIVE DEFENSE
Defendant fully tendered and/or performed all contractual, statutory, and all other duties owed to
Plaintiff under applicable law, if any. Therefore, the Complaint, and the causes of action therein, are
barred.
TWENTY-SECOND AFFIRMATIVE DEFENSE
The essential terms and conditions of the alleged contract or agreement referenced in the Complaint were and are so vague, indefinite, ambiguous, and uncertain that no mutual assent ever
occurred. Therefore, no express or implied contracts or agreements were ever formed between the parties.
TWENTY-EIGHTH AFFIRMATIVE DEFENSE
Defendant has performed all acts and obligations required of him under the contracts or
agreements, if any, to which he was party, other than those rendered impossible due to the actions or
inactions of Plaintiff.
THIRTIETH AFFIRMATIVE DEFENSE
Plaintiff has not set forth the basis of its fraud claim with the requisite specificity required by
statute and thus, Plaintiff's fraud claim against Defendant is barred.
on and on........ they go.....
Read the 31 listed defenses in the
DAVID KOOS' ANSWER TO COMPLAINT
https://drive.google.com/file/d/14X8buWis_OB5GoLw5mPwQEYMHA-fNUVI/view
folder with court docs.
https://drive.google.com/drive/folders/1T9AfNkC1HfO8a-R21zNJhLj91Tp_hB2e
-------------------------------------------------------------------
Mr Koos started tacking a different direction and filed 31 actions in defense and asked for a trial that would involve all the usual discovery and depos so I dont think he was too worried about his defense.
Here are the majority of filings in the case if anyone would like to go thru and give a better overview of the case and possible reasons for the defense that seems to point at other issues than monetary payment that could be involved here?
https://drive.google.com/drive/folders/1T9AfNkC1HfO8a-R21zNJhLj91Tp_hB2e
Amended 2020 Annual Report as of May 15, 2021
https://sec.report/otc/financial-report/283820
Most certainly going forward it's going to be EYE OPENING! Current status is coming soon.. Thanks for all your Input and DD....
$RGBP Listed In another Great NEWS article.. nothing but good will come from all this Research from a key player...
Hematopoietic Stem Cell Transplant Market Global Industry Demand, Innovative, Research Report, Future Estimation And Forecast[2029]
Post author
By news@researchnester.com
Post date
May 17, 2021
Research Nester released a report titled “Hematopoietic Stem Cell Transplant Market: Global Demand Analysis & Opportunity Outlook 2029” which delivers a detailed overview of the hematopoietic stem cell transplant market in terms of market segmentation by transplant type, disease indication, application, end user, and by region.
Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.
With the increasing prevalence of hematopoietic diseases, advancement in medical technology, and the rising demand for a cure for various medical conditions, the global hematopoietic stem cell transplant market is expected to witness growth by a substantial CAGR during the forecast period, i.e., 2021 – 2029. Research from secondary sources stated that in the year 2021 in the United States, more than 129,000 people are evaluated to be diagnosed with a serious blood disorder. Moreover, an increase in research-based initiatives on a global level is another significant factor that is expected to drive the growth of the market.
Download Sample of This Strategic Report: https://www.researchnester.com/sample-request-2889
The hematopoietic stem cell transplant market is segmented on the basis of transplant type into allogeneic and autologous types. Amongst these, the segment for allogeneic transplant is evaluated to occupy the largest market share as the process creates a new immune system once the donated cells are embedded into the body of the patient.
Geographically, the global hematopoietic stem cell transplant market is segmented into five major regions, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The market in North America is predicted to grab the largest share in 2021 owing to the growing prevalence of leukemia and lymphoma, and an increase in demand for improved treatment solutions in the region.
Increasing Prevalence of Hematopoietic Disorders
The number of people who develop blood-related diseases requiring hematopoietic stem cell transplants is on the rise. This has led to a surge in the number of researches being conducted in the field of healthcare, and the development of transplantation procedures with higher success rates, which are the major factors anticipated to boost the growth of the global hematopoietic stem cell transplant market over the forecast period.
“The Final Report will cover the impact analysis of COVID-19 on this industry.”
Download/Request Sample Copy of Strategic Report: https://www.researchnester.com/sample-request-2889
However, the expensive cost of transplant treatment is projected to act as a hindrance to the hematopoietic stem cell transplant market in the coming years.
This report also provides the existing competitive scenario of some of the key players of the global hematopoietic stem cell transplant market which includes company profiling of Lonza Group Ltd. (SWX: LONN), Escape therapeutics, Inc., Regen BioPharma, Inc. (OTCMKTS: RGBP), ThermoGenesis Holdings, Inc. (NASDAQ: THMO), CSG-BIO Company, Inc., CBR Systems, Inc., Pluristem Inc. (NASDAQ: PSTI), Global Cord Blood Corporation (NYSE: CO), ViaCord, LLC, and Cynata Therapeutics Limited (ASX: CYP). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials, and recent news and developments. On the whole, the report depicts a detailed overview of the global hematopoietic stem cell transplant market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities, and other stakeholders to align their market-centric strategies according to the ongoing and expected trends in the future.
About Research Nester
Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates, and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.
Contact for more Info:
AJ Daniel
Email: info@researchnester.com
story Link: https://murphyshockeylaw.net/news/2974614/hematopoietic-stem-cell-transplant-market-global-industry-demand-innovative-research-report-future-estimation-and-forecast2029/
You are over the target with that..
EXACTLY Thanks For ALL your posts.... Regen Biopharma, Inc. (the “Company”) has begun the process of reviving patent applications of the Company filed with the United States Patent and Trademark Office (“USPTO”) which have been classified as abandoned by the USPTO.
Legal services in connection with the abovementioned revival activities are being provided by Marc Baumgartner of Baumgartner Patent Law. Mr. Baumgartner has over 20 years of experience in the field of intellectual property law.
https://www.otcmarkets.com/filing/html?id=14935704&guid=srBnUpMNANS6Lth
David Koos is not getting all this lined up for nothing. I do see buyout as huge near term ongoing pontential here because of his attention to $RGBP details right now and not the PPS being his focus like a pump.
WAIT AND SEE.... ALL JMO
Oh Sid.... From that article it says..
The 12 Abandoned Patents list to be revived.
REGEN BIOPHARMA INC : Other Events (form 8-K)
05/07/2021 | 02:44pm EDT
Regen Biopharma, Inc. (the "Company") has begun the process of reviving patent applications of the Company filed with the United States Patent and Trademark Office ("USPTO") which have been classified as abandoned by the USPTO.
Legal services in connection with the abovementioned revival activities are being provided by Marc Baumgartner of Baumgartner Patent Law. Mr. Baumgartner has over 20 years of experience in the field of intellectual property law.
Application/PCT #Title of InventionStatus that may be revived...
13897735
ACCELERATION OF HEMATOPOIETIC RECONSTITUTION BY PLACENTAL ENDOTHELIAL AND ENDOTHELIAL PROGENITOR CELLS
Abandoned -- Failure To Respond To An Office Action
13957427
CELLS, COMPOSITIONS, AND TREATMENT METHODS FOR STIMULATION OF HEMATOPOIESIS
Abandoned -- Failure To Respond To An Office Action
13957431
CANCER THERAPY BY EX VIVO ACTIVATED AUTOLOGOUS IMMUNE CELLS
Abandoned -- Failure To Respond To An Office Action
14854136
STIMULATION OF IMMUNITY TO TUMOR SPECIFIC AND ENDOTHELIAL SPECIFIC PROTEINS BY IN VIVO DC ATTRACTION AND MATURATION
Abandoned -- Failure To Respond To An Office Action
14954902
IMMUNE MODULATION BY TLR ACTIVATION FOR TREATMENT OF FILOVIRUS INFECTIONS INCLUDING EBOLA
Abandoned -- Failure To Respond To An Office Action
15162370
ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES
Response To Non-Final Office Action Entered And Forwarded To Examiner
15250877
TREATMENT OF LIVER CANCER THROUGH EMBOLIZATION DEPOT DELIVERY OF BORIS GENE SILENCING AGENTS
Abandoned -- Failure To Respond To An Office Action
15364111
SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY
Response To Non-Final Office Action Entered And Forwarded To Examiner
15431681
METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION
Abandonment For Failure To Correct Drawings/Oath/NonPub Request
15494358
UNIVERSAL DONOR CHECKPOINT INHIBITOR SILENCED/GENE EDITED CORD BLOOD KILLER CELLS
Abandoned -- Failure To Pay Issue Fee
17010720
STIMULATION OF T REGULATORY CELLS BY CANNABIDIOL AS A MEANS OF TREATING ARTHRITIS AND AUTOIMMUNITY
Application Dispatched From Preexam, Not Yet Docketed
62363588
SMALL MOLECULE MODULATORS OF NR2F6 ACTIVITY
Provisional Application Expired
TDA has DSCR at .026 up 8.33% buyers lining up...
Agreed100% MMs scrambling to make big Bucks and clean up before the 22nd..
SO KNOWING THAT $ONPH would do a contract with RGBP. Try again...
ALL we need to realize this is a Biopharma company with patented possible cures.. yes cures for some of the worst cancers that are known to man and animals alike. Would you not think big pharma is going to put pressure on this through hedge funds and MMs to break the retail investor and drive it down. Any wonder why its trading like this? I know what I own Just sayin.. $RGBP
Just as I thought a worthless dingleberry 8 ball describes it perfectly.